ALACHUA – Alachua-based entrepreneur Mitch Glaeser, co-founder of San Felasco Tech City, is taking another step toward building a locally based biotechnology company with a global reach as Synvitta Diagnostics moves its developing medical testing technology closer to commercial-scale production.
Synvitta, the Alachua-based diagnostics company co-founded by Glaeser and scientist Rainara Almeida, announced Aug. 13 that it has entered into a long-term manufacturing partnership with Quommni Technologies for its next generation of diagnostic reader systems.
The agreement represents a shift from developing the company’s technology toward establishing the manufacturing infrastructure needed to produce its diagnostic equipment at scale and pursue markets in the United States and abroad.
Glaeser, Synvitta’s president and CEO, is also a founder of San Felasco Tech City, the Alachua technology and business campus developed as a hub for emerging companies, technology and entrepreneurial ventures.
Synvitta operates at UF Innovate | Sid Martin Biotech in Alachua, where the company has been developing diagnostic technology designed to provide faster results and allow healthcare professionals to test for multiple biomarkers simultaneously.
“This partnership is much more than a manufacturing agreement — it is a strategic alliance that strengthens our ability to deliver world-class diagnostic solutions to healthcare providers around the world,” Glaeser said.
“As demand for rapid, accurate, and affordable diagnostics continues to grow globally, having a trusted manufacturing partner with aligned values and long-term commitment allows Synvitta to accelerate innovation while maintaining the highest standards of quality and reliability,” he said.
Synvitta’s technology centers on multiplex diagnostic testing, which allows multiple biomarkers to be detected in a single test. The company is developing a platform that combines rapid single-target tests with scalable multiplex systems intended to simplify laboratory testing and reduce processing time.
The company has said it plans to expand its diagnostic offerings into areas including infectious diseases, autoimmune conditions and neurodegenerative disorders.
Under the new agreement, Synvitta and Quommni will collaborate on engineering, manufacturing, continued improvement and commercialization support for Synvitta’s proprietary diagnostic reader platform.
The companies did not disclose financial terms of the agreement.
The agreement has a multi-year initial term with performance-based exclusivity. It also includes provisions for engineering cooperation, executive oversight, supply continuity and expanding manufacturing capacity as Synvitta develops additional products.
Synvitta will retain ownership of its proprietary technologies, future product developments, tooling and strategic improvements developed through the collaboration, according to the company.
The companies have also established measures intended to protect against production disruptions as Synvitta expands into additional markets. Those include manufacturing documentation, transition planning, escrow provisions and continuity-of-supply safeguards.
Quommni Technologies specializes in precision instrumentation, medical technology manufacturing and helping companies transition complex technologies into commercial production.
“We are honored to have been selected as Synvitta’s strategic manufacturing partner,” Quommni Chief Technology Officer Gianmarco Suarez said. “From our earliest discussions, it was clear that Synvitta is building a diagnostic platform with the potential to make a meaningful impact on healthcare worldwide.”
Suarez said Quommni will provide engineering and manufacturing expertise as Synvitta works to bring its technologies to market.
“This partnership reflects a shared commitment to quality, continuous innovation, and long-term collaboration, and we look forward to supporting Synvitta as it expands into global markets,” he said.
The manufacturing agreement builds on Synvitta’s broader development efforts in Alachua’s biotechnology sector.
Glaeser brings a business development and entrepreneurial background to the company, while Almeida, Synvitta’s co-founder and chief scientific officer, leads its scientific research efforts. Their partnership combines the business and research components needed to develop and eventually commercialize the company’s diagnostic technology.
The company has said its goal is to integrate new diagnostic tools into existing laboratory systems without adding complexity while maintaining high levels of sensitivity and reliability.
For Synvitta, the Quommni agreement addresses another component of that process: establishing the manufacturing capacity needed if its technology moves into broader commercial use.
“Our vision has always been to build a diagnostics company capable of competing on a global stage,” Glaeser said. “This partnership significantly strengthens our manufacturing capabilities while allowing our internal team to remain focused on innovation, product development, regulatory expansion, and delivering new diagnostic solutions that improve patient care worldwide.”
The agreement positions Synvitta to increase manufacturing capacity as it pursues clinical, laboratory and point-of-care markets while continuing to develop its technology from its base in Alachua.
# # #
email editor@
alachuatoday.com
